Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome Abstract #840

Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).

Aim(s): To evaluate the effect of cumulative dose (CD) on survival in patients (pts) treated with everolimus for advanced pNETs.

Materials and methods: Twelve pts with advanced pNETs were treated with everolimus. Pts were stratified into two groups with CD<1500 mg (Group A) v. CD≥1500 mg (Group B). ROC curve analysis was performed to determine the 1500 mg cut-off value. Overall survival (OS) was estimated using Kaplan-Meier method.

Conference: 11th Annual ENETS Conference 2014 (2014)

Category: Medical treatment - Targeted therapies

Presenting Author: Rossana Berardi

Authors: Berardi R, Torniai M, Onofri A, Partelli S, Guglielmi S, Gucciardino C, Savini A, Ferretti B, Enrica T, Giustini L, Falconi M, Cascinu S

Keywords: pancreatic neuroendocrine tumor, targeted therapy, mTOR inhibitors, everolimus, cumulative dose

To read results and conclusion, please login ...

Further abstracts you may be interested in

#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors

Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.

Conference: 7th Annual ENETS Conference (2010)

Category: Clinical

Presenting Author: Kjell Öberg

Authors: Öberg K, Yao J C

Keywords: neuroendocrine tumors, mammalian target of rapamycin, somatostatin analogs, vascular endothelial growth factor, cytotoxic therapy, interferon-alpha, controlled clinical trials

#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs

Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.

Conference: 8th Annual ENETS Conference (2011)

Category: Clinical

Presenting Author: MD Maria Cristina De Martino

Authors: De Martino M C, Ducreux M, Dromain C, Duvillard P, Guigay J, ...

Keywords: everolimus, mTOR, RECIST, pancreas, neuroendocrine, tumor, proliferative index, predictor

#701 High Expression of Mammalian Target of Rapamycin (mTOR) in NF1-Related Periampullary Neuroendocrine Tumors

Introduction: Neurofibromatosis type 1 (NF1) is a rare inherited disorder associated with cutaneous lesions and neoplasms in the nervous and gastroenteropancreatic systems, including periampullary NETs. NF1-coded protein, neurofibromin, is a tumor suppressor that negatively regulates the mammalian target of rapamycin (mTOR). Preclinical in vitro and in vivo studies demonstrated a constitutive activation of mTOR pathway associated with significant antineoplastic effects of mTOR inhibitors in NF1-related glial tumor models.

Conference: 10th Annual ENETS Conference 2013 (2013)

Category: Surgical treatment

Presenting Author: MD Paola Razzore

Authors: Razzore P, Volante M, Russolillo N, Motta M, ...

Keywords: NF1, periampullar NETs, mTOR

#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors

Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.

Conference: 10th Annual ENETS Conference 2013 (2013)

Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys

Presenting Author: Concetta Sciammarella

Authors: Sciammarella C, Pivonello C, Sarnataro M, Marotta V, ...

Keywords: mTOR pathway, everolimus, pancreatic NET, bronchial carcinoids

#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.

Conference: 11th Annual ENETS Conference 2014 (2014)

Category: Medical treatment - Others

Presenting Author: Amandine Berdelou

Authors: Berdelou A, Malka D, Leboulleux S, Boige V, ...

Keywords: pNets